vs

Side-by-side financial comparison of EASTERN CO (EML) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $55.3M, roughly 1.4× EASTERN CO). On growth, EASTERN CO posted the faster year-over-year revenue change (-22.4% vs -36.9%). EASTERN CO produced more free cash flow last quarter ($3.1M vs $-6.6M). Over the past eight quarters, EASTERN CO's revenue compounded faster (-0.6% CAGR vs -34.4%).

China Eastern Airlines is a major airline in China, headquartered in Changning, Shanghai. It is one of the three major airlines in the country, along with Air China and China Southern Airlines.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

EML vs MED — Head-to-Head

Bigger by revenue
MED
MED
1.4× larger
MED
$75.1M
$55.3M
EML
Growing faster (revenue YoY)
EML
EML
+14.5% gap
EML
-22.4%
-36.9%
MED
More free cash flow
EML
EML
$9.7M more FCF
EML
$3.1M
$-6.6M
MED
Faster 2-yr revenue CAGR
EML
EML
Annualised
EML
-0.6%
-34.4%
MED

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
EML
EML
MED
MED
Revenue
$55.3M
$75.1M
Net Profit
$578.9K
Gross Margin
22.3%
69.4%
Operating Margin
3.1%
-10.4%
Net Margin
1.0%
Revenue YoY
-22.4%
-36.9%
Net Profit YoY
103.8%
EPS (diluted)
$0.10
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EML
EML
MED
MED
Q4 25
$75.1M
Q3 25
$55.3M
$89.4M
Q2 25
$70.2M
$105.6M
Q1 25
$63.3M
$115.7M
Q4 24
$64.3M
$119.0M
Q3 24
$71.3M
$140.2M
Q2 24
$72.6M
$168.6M
Q1 24
$64.6M
$174.7M
Net Profit
EML
EML
MED
MED
Q4 25
Q3 25
$578.9K
$-2.3M
Q2 25
$3.4M
$2.5M
Q1 25
$1.9M
$-772.0K
Q4 24
$1.3M
Q3 24
$-15.3M
$1.1M
Q2 24
$3.5M
$-8.2M
Q1 24
$1.9M
$8.3M
Gross Margin
EML
EML
MED
MED
Q4 25
69.4%
Q3 25
22.3%
69.5%
Q2 25
23.3%
72.6%
Q1 25
22.4%
72.8%
Q4 24
23.6%
74.1%
Q3 24
25.5%
75.4%
Q2 24
25.4%
73.2%
Q1 24
23.9%
72.8%
Operating Margin
EML
EML
MED
MED
Q4 25
-10.4%
Q3 25
3.1%
-4.6%
Q2 25
4.5%
-1.0%
Q1 25
5.1%
-1.1%
Q4 24
6.1%
0.6%
Q3 24
9.5%
1.5%
Q2 24
8.3%
-4.7%
Q1 24
5.3%
4.5%
Net Margin
EML
EML
MED
MED
Q4 25
Q3 25
1.0%
-2.5%
Q2 25
4.9%
2.3%
Q1 25
3.1%
-0.7%
Q4 24
2.0%
Q3 24
-21.5%
0.8%
Q2 24
4.8%
-4.8%
Q1 24
3.0%
4.8%
EPS (diluted)
EML
EML
MED
MED
Q4 25
$-1.64
Q3 25
$0.10
$-0.21
Q2 25
$0.56
$0.22
Q1 25
$0.32
$-0.07
Q4 24
$0.22
$0.08
Q3 24
$-2.46
$0.10
Q2 24
$0.56
$-0.75
Q1 24
$0.31
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EML
EML
MED
MED
Cash + ST InvestmentsLiquidity on hand
$9.2M
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$124.3M
$198.9M
Total Assets
$220.0M
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EML
EML
MED
MED
Q4 25
$167.3M
Q3 25
$9.2M
$173.5M
Q2 25
$9.1M
$162.7M
Q1 25
$10.2M
$164.6M
Q4 24
$16.1M
$162.3M
Q3 24
$9.7M
$170.0M
Q2 24
$2.0M
$163.5M
Q1 24
$2.1M
$156.4M
Total Debt
EML
EML
MED
MED
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$42.2M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
EML
EML
MED
MED
Q4 25
$198.9M
Q3 25
$124.3M
$214.7M
Q2 25
$124.4M
$216.0M
Q1 25
$121.0M
$211.0M
Q4 24
$120.7M
$210.1M
Q3 24
$119.2M
$207.3M
Q2 24
$136.5M
$205.3M
Q1 24
$134.5M
$211.0M
Total Assets
EML
EML
MED
MED
Q4 25
$248.0M
Q3 25
$220.0M
$268.2M
Q2 25
$229.4M
$269.3M
Q1 25
$232.3M
$280.0M
Q4 24
$235.3M
$284.2M
Q3 24
$244.2M
$291.2M
Q2 24
$255.9M
$293.5M
Q1 24
$253.9M
$302.8M
Debt / Equity
EML
EML
MED
MED
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.35×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EML
EML
MED
MED
Operating Cash FlowLast quarter
$3.1M
$-5.3M
Free Cash FlowOCF − Capex
$3.1M
$-6.6M
FCF MarginFCF / Revenue
5.5%
-8.8%
Capex IntensityCapex / Revenue
0.1%
1.8%
Cash ConversionOCF / Net Profit
5.38×
TTM Free Cash FlowTrailing 4 quarters
$12.3M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EML
EML
MED
MED
Q4 25
$-5.3M
Q3 25
$3.1M
$12.1M
Q2 25
$3.8M
$-3.4M
Q1 25
$-1.8M
$3.4M
Q4 24
$11.0M
$-4.9M
Q3 24
$-2.9M
$9.1M
Q2 24
$8.4M
$13.1M
Q1 24
$2.8M
$7.3M
Free Cash Flow
EML
EML
MED
MED
Q4 25
$-6.6M
Q3 25
$3.1M
$10.8M
Q2 25
$3.0M
$-4.8M
Q1 25
$-2.7M
$1.9M
Q4 24
$9.0M
$-7.2M
Q3 24
$-7.7M
$7.7M
Q2 24
$7.3M
$11.1M
Q1 24
$1.1M
$5.4M
FCF Margin
EML
EML
MED
MED
Q4 25
-8.8%
Q3 25
5.5%
12.0%
Q2 25
4.3%
-4.5%
Q1 25
-4.3%
1.6%
Q4 24
13.9%
-6.1%
Q3 24
-10.8%
5.5%
Q2 24
10.1%
6.6%
Q1 24
1.7%
3.1%
Capex Intensity
EML
EML
MED
MED
Q4 25
1.8%
Q3 25
0.1%
1.5%
Q2 25
1.1%
1.3%
Q1 25
1.3%
1.3%
Q4 24
3.2%
1.9%
Q3 24
6.7%
1.0%
Q2 24
1.5%
1.1%
Q1 24
2.6%
1.1%
Cash Conversion
EML
EML
MED
MED
Q4 25
Q3 25
5.38×
Q2 25
1.09×
-1.36×
Q1 25
-0.95×
Q4 24
8.41×
Q3 24
8.04×
Q2 24
2.40×
Q1 24
1.43×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons